Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scribe Therapeutics IncfiledCriticalScribe Therapeutics Inc
Priority to CL2023000272ApriorityCriticalpatent/CL2023000272A1/en
Publication of CL2023000272A1publicationCriticalpatent/CL2023000272A1/en
En la presente se proporcionan sistemas de CasX y componentes de estos, incluidas proteínas CasX variantes y ácidos nucleicos guia variantes (ANg). Las proteínas CasX variantes y ANg variantes de la divulgación muestran por lo menos una característica mejorada cuando se los compara con una proteína CasX de referencia o un ANg de referencia de la divulgación. En algunas instancias, las variantes tienen una o más funciones mejoradas del complejo de ribonucleoproteínas de CasX. En algunas instancias, las variantes tienen una o más funciones mejoradas del complejo de ribonucleoproteínas de CasX.Provided herein are CasX systems and components thereof, including variant CasX proteins and variant guide nucleic acids (gNAs). The variant CasX proteins and variant ANgs of the disclosure show at least one improved feature when compared to a reference CasX protein or reference ANg of the disclosure. In some instances, variants have one or more enhanced functions of the CasX ribonucleoprotein complex. In some instances, variants have one or more enhanced functions of the CasX ribonucleoprotein complex.
Method for producing oxalate oxidases having optical activity near physiological pH and use of such recombinant oxalate oxidases in the treatment of oxalate-related diseases